

# Combination Letemovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients

NCT07235683

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	University Health Network, Toronto
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Recipient of a lung transplant.
- Has confirmed CMV viremia with a viral load  $\geq 1000$  IU/mL and will receive or has just started SOC antiviral treatment in the past 72h as per the decision of the treating physician.

### Exclusion (8)

- Renal failure with Creatinine clearance  $<15$  mL/min or requiring dialysis
- Severe hepatic impairment (Child-Pugh Class C)
- Participating in another interventional clinical trial
- Combined transplant (e.g heart-lung, lung-liver)
- Known allergy or contraindication to any of the antiviral medications
- ... and 3 more (see full listing online)

## Locations (1 total)

---

University Health Network, Toronto General Hospital, Toronto, Ontario, Canada